Analysts Overlook Lilly’s Liver Concerns Too Quickly, Experts Question Risk Assessment

Biotechnology analysts are facing scrutiny over their rapid dismissal of Eli Lilly’s liver safety concerns tied to its experimental diabetes drug, tirzepatide. Critics argue that the rush to downplay risks may overlook critical long-term implications for patient safety and regulatory approval.

Key Biotech Developments This Week

Vertex Pharma Halts mRNA Cystic Fibrosis Therapy Due to Tolerability Issues

Vertex Pharmaceuticals announced its first-quarter earnings, which aligned with market expectations. However, the company revealed it was discontinuing the development of VX-522, an early-stage mRNA-based therapy for cystic fibrosis, citing poor tolerability in clinical trials. The drug was being developed in collaboration with Moderna.

Pfizer and Alkermes Report Earnings Amid Market Activity

Pfizer and Alkermes also released their first-quarter earnings reports, contributing to the broader biotech sector’s financial landscape.

Viridian Therapeutics Achieves Positive Phase 3 Results for Elegrobart

Viridian Therapeutics announced positive top-line results from a Phase 3 study evaluating elegrobart in patients with chronic thyroid eye disease. The drug’s performance in the trial marks a significant milestone for the company’s pipeline.

Cytokinetics’ Myqorzo Meets Dual Efficacy Goals in Genetic Heart Disease Study

Cytokinetics reported that its drug Myqorzo met both primary efficacy endpoints in a study involving patients with non-obstructive hypertrophic cardiomyopathy, a rare inherited heart disorder. The drug demonstrated significant improvements in heart failure symptoms and cardiovascular fitness.

The full analysis of these developments, including deeper insights into Lilly’s liver safety concerns and their potential impact on tirzepatide’s future, is available to STAT+ subscribers.